<DOC>
	<DOC>NCT03030300</DOC>
	<brief_summary>To evaluate the long-term remission rate of short-term intensive insulin (STII) therapy in newly diagnosed type 2 diabetes outpatients and investigate the predictors contributing to the remission rate.</brief_summary>
	<brief_title>Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Newly diagnosed, insulinnaive type 2 diabetes outpatients Diabetes duration less than 1 year Various acute complications Hepatic transaminase &gt;2.5x normal reference value (glutamicpyruvic transminase&gt;100U/L, glutamicoxalacetic transaminase &gt; 100U/L) Abnormal renal functions (serum cretinine&gt;the normal reference value) Cardiac insufficiency (America NYHA caediac function &gt;3) Type 1 diabetes mellitus Ongoing hormone therapy Women in gestation and lactation Patients with other endocrine disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>remission</keyword>
	<keyword>short-term intensive insulin therapy</keyword>
</DOC>